Cancers gynécologiques

GLORIOSA

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA).
  • Open at Paris since : 13/09/2024
  • Target : Adult
  • Phase : Phase III

Trial description

To compare progression-free survival (PFS), as assessed by the investigator per the;Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), after;platinum-based chemotherapy (doublet) plus bevacizumab and randomized to;maintenance mirvetuximab soravtansine (MIRV) plus bevacizumab (Arm 1) versus;bevacizumab alone (Arm 2);- PFS will also be assessed, as a sensitivity analysis, by a blinded independent;central review (BICR) in the same patient population.
Url of the trial

Main investigator